New study suggests it costs $1.3B in R&D investment to bring a drug to market. How did it get there?
Politicians, pundits and patient groups now have a new number at their disposal when drugmakers cite high R&D costs — as much as $2.8 billion in current dollars — to justify their pricing decisions: $1.3 billion in mean investment to bring a drug to market.
The estimated mean cost is the central finding reported in a new JAMA study, which set out to obtain its own answer to the long-running debate of how much it costs to get a therapy to patients. But the figure doesn’t capture the range of costs broken by therapeutic area, which can range from $765.9 million for nervous system drugs to $2.77 billion for cancer and immunology treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.